Comparisons of ACR TI-RADS, ATA guidelines, Kwak TI-RADS, and KTA/KSThR guidelines in malignancy risk stratification of thyroid nodules

2020 ◽  
pp. 1-14 ◽  
Author(s):  
Wei-Bing Zhang ◽  
Hui-Xiong Xu ◽  
Yi-Feng Zhang ◽  
Le-Hang Guo ◽  
Shi-Hao Xu ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Thyroid Nodules ◽  
Malignancy Risk

scholarly journals European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS

2017 ◽  
Vol 6 (5) ◽  
pp. 225-237 ◽  
Author(s):  
Gilles Russ ◽  
Steen J. Bonnema ◽  
Murat Faik Erdogan ◽  
Cosimo Durante ◽  
Rose Ngu ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Thyroid Nodules ◽  
Malignancy Risk ◽  
The Eu

Malignancy risk stratification and FNA recommendations for thyroid nodules: A comparison of ACR TI-RADS, AACE/ACE/AME and ATA guidelines

2020 ◽  
Vol 41 (6) ◽  
pp. 102625 ◽  
Author(s):  
Jian-Yun Peng ◽  
Fu-Shun Pan ◽  
Wei Wang ◽  
Zhu Wang ◽  
Quan-Yuan Shan ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Thyroid Nodules ◽  
Malignancy Risk

scholarly journals Combination of ultrasound and molecular testing in malignancy risk estimate of Bethesda category IV thyroid nodules: results from a single-institution prospective study

2021 ◽  
Author(s):  
M. Marina ◽  
M. C. Zatelli ◽  
M. Goldoni ◽  
P. Del Rio ◽  
L. Corcione ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Somatic Mutation ◽  
Thyroid Nodules ◽  
Point Mutations ◽  
Needle Aspiration ◽  
Risk Estimate ◽  
Molecular Testing ◽  
Malignancy Risk ◽  
Needle Aspiration Cytology ◽  
Codon 61

Abstract Purpose Malignancy prediction in indeterminate thyroid nodules is still challenging. We prospectively evaluated whether the combination of ultrasound (US) risk stratification and molecular testing improves the assessment of malignancy risk in Bethesda Category IV thyroid nodules. Methods Ninety-one consecutively diagnosed Bethesda Category IV thyroid nodules were prospectively evaluated before surgery by both ACR- and EU-TIRADS US risk-stratification systems and by a further US-guided fine-needle aspiration cytology (FNAC) for the following molecular testing: BRAFV600E, N-RAS codons 12/13, N-RAS codon 61, H-RAS codons 12/13, H-RAS codon 61, K-RAS codons 12/13, and K-RAS codon 61 point-mutations, as well as PAX8/PPARγ, RET/PC1, and RET/PTC 3 rearrangements. Results At histology, 37% of nodules were malignant. No significant association was found between malignancy and either EU- or ACR-TIRADS. In total, 58 somatic mutations were identified, including 3 BRAFV600E (5%), 5 N-RAS 12/13 (9%), 13 N-RAS 61 (22%), 7 H-RAS 12/13 (12%), 11 H-RAS 61 (19%), 6 K-RAS 12/13 (10%), 8 K-RAS 61 (14%) mutations and 2 RET/PTC1 (4%), 0 RET/PTC 3 (0%), 3 PAX8/PPARγ (5%) rearrangements. At least one somatic mutation was found in 28% and 44% of benign and malignant nodules, respectively, although malignancy was not statistically associated with the outcome of the mutational test. However, the combination of ACR-, but not EU-, TIRADS with the presence of at least one somatic mutation, was significantly associated with malignant histology (P = 0.03). Conclusion US risk stratification and FNAC molecular testing may synergistically contribute to improve malignancy risk estimate of Bethesda category IV thyroid nodules.

Malignancy risk stratification of thyroid nodules by TIRADS; correlation with cytological results

2015 ◽  
Author(s):  
Antonio J Martinez ◽  
Virginia Hernando ◽  
Clara Garcia ◽  
Alberto Torres ◽  
Tomas Martin
Keyword(s):  
Risk Stratification ◽  
Thyroid Nodules ◽  
Malignancy Risk
Sign in / Sign up

Export Citation Format

Share Document